Cargando…

Why do we not have a cure for rheumatoid arthritis?

CHAPTER SUMMARY: There are currently unprecedented opportunities to treat rheumatoid arthritis using well-designed, highly effective, targeted therapies. This will result in a substantial improvement in the outcome of this disorder for most affected individuals, if they can afford these therapies. Y...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Gabalawy, Hani D, Lipsky, Peter E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2002
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240144/ https://www.ncbi.nlm.nih.gov/pubmed/12110149 http://dx.doi.org/10.1186/ar568

Ejemplares similares

Oxidation in rheumatoid arthritis
por: Hitchon, Carol A, et al.
Publicado: (2004)

The Synovium in Rheumatoid Arthritis
por: Hitchon, Carol A, et al.
Publicado: (2011)

Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis
por: El-Gabalawy, Hani S, et al.
Publicado: (2004)

Genetics of rheumatoid arthritis: what have we learned?
por: Bax, Marieke, et al.
Publicado: (2011)

Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes
por: Anaparti, Vidyanand, et al.
Publicado: (2022)

Why Do We Have Fingerprints?
Publicado: (2009)

Achieving a cure for HIV infection: do we have reasons to be optimistic?
por: Le Douce, Valentin, et al.
Publicado: (2012)

Regulatory T cells in rheumatoid arthritis
por: Leipe, Jan, et al.
Publicado: (2005)

Why do we still have not a vaccine against Chagas disease?
por: Camargo, Erney Plessmann, et al.
Publicado: (2022)

Modifiable risk factors linked to the development of rheumatoid arthritis: evidence, immunological mechanisms and prevention
por: Maisha, Jeba Atkia, et al.
Publicado: (2023)

Functional genomics and rheumatoid arthritis: where have we been and where should we go?
por: Jarvis, James N, et al.
Publicado: (2010)

Circulating levels of free 25(OH)D increase at the onset of rheumatoid arthritis
por: Anaparti, Vidyanand, et al.
Publicado: (2019)

The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
por: Dwivedi, Ravi C, et al.
Publicado: (2009)

Why Do We have to Move Fluid to be Able to Breathe?
por: Fronius, Martin, et al.
Publicado: (2012)

Disparities in rheumatoid arthritis outcomes for North American Indigenous populations
por: Hitchon, Carol A, et al.
Publicado: (2023)

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
por: Schwartzman, Sergio, et al.
Publicado: (2004)

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?
por: Halilova, Karina I., et al.
Publicado: (2012)

Serum proteomic networks associate with pre-clinical rheumatoid arthritis autoantibodies and longitudinal outcomes
por: O’Neil, Liam J., et al.
Publicado: (2022)

Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters
por: Popovici, Jean, et al.
Publicado: (2021)

Myelography in the Age of MRI: Why We Do It, and How We Do It
por: Ozdoba, Christoph, et al.
Publicado: (2011)

Association of MHC and rheumatoid arthritis: Why is rheumatoid arthritis associated with the MHC genetic region? An introduction
por: Holmdahl, Rikard
Publicado: (2000)

Why Do Some Vertebrates Have Microchromosomes?
por: Srikulnath, Kornsorn, et al.
Publicado: (2021)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Fake news: Why do we believe it?
por: Beauvais, Catherine
Publicado: (2022)

How Do We Define Cure of Diabetes?
por: Buse, John B., et al.
Publicado: (2009)

Why we do what we do. A brief analysis of cancer therapies
por: Galmarini, Carlos M.
Publicado: (2020)

Sedation in non-invasive ventilation: do we know what to do (and why)?
por: Longrois, Dan, et al.
Publicado: (2014)

Nursing care and outcome in surgical patients – why do we have to care?
por: Nestler, Nadja
Publicado: (2019)

What Is the Value of Ultrasound in Individuals ‘At-Risk’ of Rheumatoid Arthritis Who Do Not Have Clinical Synovitis?
por: Di Matteo, Andrea, et al.
Publicado: (2021)

Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
por: Németh, Tamás, et al.
Publicado: (2022)

Rheumatoid arthritis: the journey in pursuit of a cure
por: Karponis, Dimitrios
Publicado: (2017)

High body mass index in rheumatoid arthritis: why we should promote physical activity
por: Hugo, M., et al.
Publicado: (2017)

Why Do We Shiver?
Publicado: (1893)

How and why do we screen for colorectal cancer?
por: Chetroiu, Diana, et al.
Publicado: (2021)

Why don’t we have an effective tuberculosis vaccine yet?
por: Davenne, Tamara, et al.
Publicado: (2016)

Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects
por: Anaparti, Vidyanand, et al.
Publicado: (2017)

Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis
por: Ochi, Takahiro, et al.
Publicado: (2007)

The challenge of early synovitis: multiple pathways to a common clinical syndrome
por: El-Gabalawy, Hani
Publicado: (1999)

Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis
por: O’Neil, Liam J., et al.
Publicado: (2021)

What is MRI bone oedema in rheumatoid arthritis and why does it matter?
por: McQueen, Fiona M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_182n4bm61vcbtdhtkl5fuo5rd7